无功能垂体大腺瘤多次切除后立体定向放射外科的国际多中心病例系列结局
回顾性多中心分析1992至2022年311例无功能垂体腺瘤患者,其中226例(72.7%)在立体定向放射外科前接受过≥2次切除。立体定向放射外科后5年和10年肿瘤控制概率分别为93.3%和86.7%;边缘剂量>14 Gy与肿瘤进展风险降低相关(HR=0.33),垂体柄最大点剂量>10 Gy与新发激素缺乏相关(HR=4.06)。
要点
- 多次切除后立体定向放射外科的5年和10年肿瘤控制概率分别为93.3%和86.7%。
- 边缘剂量>14 Gy与肿瘤进展风险降低相关(HR=0.33,95%CI 0.15-0.75,P=.008)。
- 垂体柄最大点剂量>10 Gy与新发激素缺乏相关(HR=4.06,95%CI 1.57-10.5,P=.004)。
核心结论
- 对于多次切除的无功能垂体腺瘤患者,立体定向放射外科提供有效的局部肿瘤控制且延迟性垂体功能减退风险低,作者认为对于已有2次切除的无功能垂体腺瘤患者应强烈考虑立体定向放射外科而非考虑第三次切除。
研究设计与样本
- 回顾性多中心病例系列,纳入1992至2022年诊断无功能垂体腺瘤且在立体定向放射外科前接受多次(≥2次)切除的患者,共311例(中位年龄50.2岁,IQR 18.0),其中226例(72.7%)接受过≥2次切除。
- 采用Cox回归和Kaplan-Meier曲线评估预测因素及肿瘤控制和垂体功能减退的概率。
主要发现
- 立体定向放射外科后肿瘤控制概率在5年时为93.3%(95%CI 89.9-96.9),10年时为86.7%(95%CI 81.1-92.6)。
- 中位边缘剂量为14 Gy(IQR 4.0 Gy),中位肿瘤体积为3.6 cm³(IQR 4.8)。
- 边缘剂量>14 Gy与肿瘤进展风险降低相关(HR=0.33,95%CI 0.15-0.75,P=.008)。
- 末次临床随访4.1年(IQR 6.1)时,10.1%(30/296)出现至少1种新发激素缺乏;新发激素缺乏的累积概率在立体定向放射外科后3年、5年和10年分别为6.1%(95%CI 3.0-9.1)、10.3%(95%CI 5.8-14.6)和18.9%(95%CI 11.5-25.8)。
- 立体定向放射外科至新发激素缺乏的平均潜伏期为3.3年(IQR 4.1);垂体柄最大点剂量>10 Gy与新发激素缺乏相关(HR=4.06,95%CI 1.57-10.5,P=.004)。
临床怎么用
- 作者认为对于已有2次切除的无功能垂体腺瘤患者应强烈考虑立体定向放射外科,而非考虑第三次切除。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Stereotactic radiosurgery (SRS) represents an effective treatment for nonfunctioning pituitary adenomas (NFPAs). However, no data have yet been published regarding results of SRS on NFPAs after multiple previous resections. METHODS: Retrospective multicentric data of patients diagnosed with NFPA and who underwent multiple resections (≥2) before SRS were reviewed and analyzed. The treatment interval spanned the period of 1992 to 2022. Cox regression and Kaplan-Meier curves were used to assess predictive factors and the probability of tumor control and hypopituitarism. RESULTS: Among the 311 patients (median age: 50.2 [IQR: 18.0] years), 226 (72.7%) had undergone ≥2 previous resections. The median margin dose was 14 Gy (IQR: 4.0 Gy), and the median tumor volume 3.6 cm 3 (IQR: 4.8). Overall, the probability of tumor control after SRS was 93.3% (CI 95%: 89.9-96.9) and 86.7% (CI 95%: 81.1-92.6) at 5 and 10 years, respectively. A margin dose >14 Gy was associated with a decreased risk of tumor progression (hazard ratio = 0.33, CI 95% = 0.15-0.75, P = .008). At a last clinical follow-up of 4.1 (IQR 6.1) years, 10.1% (30/296) developed at least 1 new hormone deficiency after SRS. The cumulative probability of new hormone deficiency was 6.1% (95% CI: 3.0-9.1), 10.3% (95% CI: 5.8-14.6), and 18.9% (95% CI: 11.5-25.8) at 3, 5, and 10 years after SRS, respectively. The average latency between SRS and development of new hormone deficiencies was 3.3 years (IQR 4.1). A maximum point dose to the pituitary stalk >10 Gy was associated with a new deficiency (hazard ratio = 4.06, CI 95% = 1.57-10.5, P -value = .004). CONCLUSION: For patients with NFPA with multiple previous resections, SRS offers effective local tumor control and a low risk of delayed hypopituitarism for managing these challenging adenomas. SRS should be strongly considered in patients with NFPA with 2 previous resections compared with considering a third resection.
引用
- Grogan D, Dumot C, Mantziaris G, et al. Outcomes Associated With Stereotactic Radiosurgery After Multiple Resections of Nonfunctioning Pituitary Macroadenomas: An International, Multicenter Case Series. Neurosurgery. 2024. PMID: 39508579. doi:10.1227/neu.0000000000003262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。